polidocanol and Kidney-Diseases--Cystic

Topics: Child; Cysts; Humans; Kidney Diseases, Cystic; Laparoscopy; Polidocanol; Sclerotherapy; Treatment Outcome

To compare the efficacy and safety of percutaneous ethanol and polidocanol sclerotherapy in the management of simple renal cysts.. Between 2008 and 2013, symptomatic Bosniak type I renal cysts with a diameter larger than 5 cm in ultrasonography (US) or computed tomography were included in the study and divided into two groups. Group 1 patients were treated by US-guided percutaneous polidocanol sclerotherapy, and group 2 patients were treated by US-guided percutaneous ethanol sclerotherapy. The pre-operative and postoperative US findings were documented to compare the cyst recurrence and the reduction in cyst size. Success was defined as complete or partial: as >90% reduction or 50-90% reduction in cyst size, respectively. Failure was defined as <50% reduction in cyst size. The success rates of two groups were compared. Intraoperative pain was assessed using a visual analog scale (VAS) just after the operation.. The median follow-up period was 36 months (range 12-76) in group 1 and 39 months (range 10-78) in group 2. Group 1 consists of 86 patients with 89 simple renal cysts, and group 2 consists of 57 patients with 57 simple renal cysts. Anatomical success was documented in 49 (55.1%) and 48 (84.2%) cysts in groups 1 and 2, respectively (p < 0.001). Clinical success was seen in 56 (65.1%) and 43 (75.4%) patients in groups 1 and 2, respectively. Major complication was detected in only one patient in group 2 (aseptic psoas abscess), and there was not any major complication in group 1. Minor complications had occurred in ten patients in group 2 (microscopic hematuria in six patients and fever and nausea in four patients) and in eight patients in group 1 (microscopic hematuria in six patients and fever and nausea in two patients). The mean VAS scores were 21 ± 1.04 and 4.26 ± 1.99 in ethanol and polidocanol groups, respectively (p < 0.001). Ethanol was found to be significantly painful, compared to polidocanol in the sclerotherapy of simple renal cysts.. Although the complication rates and VAS scores of ethanol sclerotherapy are higher than those of polidocanol sclerotherapy, its success rates appear to be also higher. The decision of which sclerosing agent will be used should be based on patients' comorbidities, cyst location and the surgeon's experience.

Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Local; Ethanol; Female; Follow-Up Studies; Humans; Kidney Diseases, Cystic; Male; Middle Aged; Polidocanol; Polyethylene Glycols; Retrospective Studies; Sclerosing Solutions; Sclerotherapy; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

Methodology and long-term results of treatment of uncomplicated kidney cysts by percutaneous sclerotherapy with polidocanol are presented. Between 1991 and 1998, 132 patients with 151 kidney cysts were treated by percutaneous sclerotherapy with polidocanol as the sclerosing agent. The average volume of the cysts was 288 ml. Over a mean period of 25.8 months, 118 patients with 132 cysts were followed up. In 56% of the cysts treated the cystic cavity disappeared completely, and in 30% the remaining volume was less than 10% of the initial volume. The existing symptoms before intervention remained unchanged only in four (3.4%) patients. The morbidity of the method was 9% and surgical reintervention was not necessary. There was no mortality. The mean hospitalization was 1.06 days. Percutaneous sclerotherapy of uncomplicated kidney cysts with polidocanol offers a high rate of success without the costs and invasiveness associated with laparoscopic surgery and also without the need for repeated interventions associated with sclerotherapy performed with ethanol.

Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Kidney Diseases, Cystic; Male; Middle Aged; Polidocanol; Polyethylene Glycols; Sclerotherapy; Treatment Outcome; Urography

Simple renal cysts were treated by aspiration and injection of the sclerosing agent 3% polidocanol (Aetoxisclerol) in 15 patients. All patients were followed up by ultrasound for 1-24 months. The age ranged from 35 to 81 years. There was 1 recurrence at 1 month. The efficacy of this treatment was 93%. Fourteen cysts completely disappeared, and no recurrence occurred after 1 year. Complications, such as microscopic hematuria, fever and infection, were not observed. The technique of polidocanol sclerotherapy was effective and safe.

Topics: Female; Follow-Up Studies; Humans; Kidney Diseases, Cystic; Male; Middle Aged; Polidocanol; Polyethylene Glycols; Sclerosing Solutions; Sclerotherapy; Suction; Time Factors; Treatment Outcome

First experiences are reported with percutaneous sclerosing therapy of cysts with polidocanol (aethoxysklerol 1%) using ultrasound for needle guidance. They cover two patients with symptomatic cysts of the liver and a patient with polyglobulinemia and an erythropoietin-producing renal cyst. These experiences are compared to previously reported ones.

Topics: Adult; Aged; Cysts; Female; Humans; Kidney Diseases, Cystic; Liver Diseases; Male; Polidocanol; Polyethylene Glycols; Sclerosing Solutions; Ultrasonography

Topics: Aged; Female; Humans; Kidney Diseases, Cystic; Male; Middle Aged; Polidocanol; Polycystic Kidney Diseases; Polyethylene Glycols; Radiography; Sclerosing Solutions

A report is given on the medicinal sclerosing of renal cysts by percutaneous treatment of 15 patients of the age of about 50 to 70 years. By intracaval injection of Aethoxysklerol in a solution of 2% the vessels of the cysts wall are obliterated and the tissue is sclerosed. The described technique avoids incorrect application as well as complications and major strain for the patients. True recurrences are obviously seldom. The report indicates that any evidence of a tumour disease apart from the cysts must bei excluded. The successful treatment shows that the percutaneous sclerosing represents a recommendable alternative to surgical operations. The efficacy and compatibility of the sclerosing agent Aethoxysklerol are particularly mentioned.

Topics: Aged; Follow-Up Studies; Humans; Kidney Diseases, Cystic; Middle Aged; Nephrostomy, Percutaneous; Polidocanol; Polycystic Kidney Diseases; Polyethylene Glycols; Sclerosing Solutions; Ultrasonography

Topics: Adolescent; Adult; Aged; Benzyl Alcohol; Benzyl Alcohols; Child; Female; Humans; Kidney Diseases, Cystic; Male; Middle Aged; Polidocanol; Polyethylene Glycols; Sclerosing Solutions; Sodium Iodide